Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer
Sonpavde, G., Matveev, V., Burke, J.M., Caton, J.R., Fleming, M.T., Hutson, T.E., Galsky, M.D., Berry, W.R., Karlov, P., Holmlund, J.T., Wood, B.A., Brookes, M., Leopold, L.
Published in Annals of oncology (01.07.2012)
Published in Annals of oncology (01.07.2012)
Get full text
Journal Article
Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma
Rao, S., Watkins, D., Cunningham, D., Dunlop, D., Johnson, P., Selby, P., Hancock, B. W., Fegan, C., Culligan, D., Schey, S., Morris, T. C. M., Lissitchkov, T., Oliver, J. W., Holmlund, J. T.
Published in Annals of oncology (01.09.2004)
Published in Annals of oncology (01.09.2004)
Get full text
Journal Article
Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116)
Oza, A.M, Elit, L, Swenerton, K, Faught, W, Ghatage, P, Carey, M, McIntosh, L, Dorr, A, Holmlund, J.T, Eisenhauer, E
Published in Gynecologic oncology (01.04.2003)
Published in Gynecologic oncology (01.04.2003)
Get full text
Journal Article